beta-Ureidopropionase Deficiency Presenting with Febrile Status Epilepticus
- 1 January 2006
- Vol. 47 (1), 215-217
- https://doi.org/10.1111/j.1528-1167.2006.00391.x
Abstract
Beta-ureidopropionase is the third enzyme in the catabolic pathway of uracil and thymine. To date, only three other patients are reported with this inborn error of metabolism. We report the clinical presentation of a male patient who presented at the age of 4 months after an ALTE-like event (ALTE = acute life-threatening event) with febrile status epilepticus. Such a clinical presentation has not been reported before in this condition. Diagnosis was based on biochemical, enzymatic and molecular studies. MRI (magnetic resonance imaging) at the age of 11 months demonstrated large subdural hematomata and global supratentorial atrophy. At that time the patient showed severe psychomotor retardation with muscular hypotonia, extremely limited visual contact and poorly controlled epilepsy. CONCLUSIONS: Pyrimidine degradation defects should be included in the differential diagnosis of convulsions, (febrile) status epilepticus, psychomotor retardation and possibly also ALTE-like eventKeywords
This publication has 4 references indexed in Scilit:
- β-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalitiesHuman Molecular Genetics, 2004
- Quantification of 5,6-Dihydrouracil by HPLC–Electrospray Tandem Mass SpectrometryClinical Chemistry, 2004
- Screening and diagnosis of ?-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urineJournal of Mass Spectrometry, 2002
- Subdural hematoma during low-dose ACTH therapy in patients with West syndromeNeurology, 2000